Physician profile

Fernando Diaz

Internal Medicine · Miami, FL

NPI 1942659842

$714.52

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $152.73 2021-2022
Esperion Therapeutics, INC. $137.10 2021
Lilly USA, LLC $136.08 2019-2021
Novo Nordisk INC $117.93 2019
Boehringer Ingelheim Pharmaceuticals, INC. $58.18 2021-2022
Janssen Pharmaceuticals, INC $45.85 2021-2022
Vanda Pharmaceuticals INC. $27.00 2021
Theratechnologies INC. $24.87 2024 Trogarzo, Egrifta
Abbvie INC. $14.78 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Fernando Diaz

$714.52

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/7222483/fernando-diaz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.